Revvity (NYSE:RVTY) Given New $172.00 Price Target at Royal Bank Of Canada

Revvity (NYSE:RVTY) had its target price increased by Royal Bank Of Canada from $135.00 to $172.00 in a report published on Wednesday morning,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock.

Several other research analysts have also issued reports on RVTY. UBS Group assumed coverage on Revvity in a research note on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price objective for the company. William Blair began coverage on shares of Revvity in a report on Monday, October 5th. They issued an “outperform” rating on the stock. Cfra upgraded shares of Revvity from a “hold” rating to a “buy” rating in a research report on Wednesday. Barclays increased their target price on shares of Revvity from $115.00 to $160.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Finally, Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Six research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $133.86.

Revvity Trading Down 2.3%

RVTY stock opened at $159.68 on Wednesday. Revvity has a 1-year low of $81.22 and a 1-year high of $171.74. The firm has a market cap of $17.82 billion, a P/E ratio of 29.46, a P/E/G ratio of 2.95 and a beta of 1.08. The business’s 50 day moving average is $146.58 and its 200-day moving average is $112.84. The company has a current ratio of 2.65, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last posted its earnings results on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.30 by $0.08. The business had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. Revvity had a return on equity of 8.64% and a net margin of 8.61%. Revvity’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the company earned $1.18 EPS. Equities analysts anticipate that Revvity will post 5.41 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Stockholders of record on Friday, January 22nd will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, January 22nd. Revvity’s dividend payout ratio is presently 13.33%.

Insider Buying and Selling

In related news, insider Maxwell Krakowiak sold 1,631 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the sale, the insider owned 14,781 shares of the company’s stock, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Tajinder S. Vohra sold 7,330 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. This trade represents a 52.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 9,045 shares of company stock worth $1,281,439 over the last quarter. 0.85% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Ascentis Independent Advisors acquired a new stake in Revvity in the first quarter worth about $29,000. Pillar Financial Advisors LLC acquired a new position in Revvity during the 3rd quarter valued at about $29,000. Heritage Family Offices LLP acquired a new position in Revvity during the 3rd quarter valued at about $37,000. Global Retirement Partners LLC acquired a new position in Revvity during the 2nd quarter valued at about $51,000. Finally, Summit Securities Group LLC boosted its stake in shares of Revvity by 294.6% in the 1st quarter. Summit Securities Group LLC now owns 663 shares of the company’s stock valued at $58,000 after purchasing an additional 495 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity beat third-quarter estimates, reporting adjusted EPS of $1.38 versus a $1.30 consensus and revenue of $728.9 million versus $694.7 million. Revenue increased 4.3% year over year, with Life Sciences strength and margin expansion cited, and the company raised its 2026 outlook. Q3 earnings and outlook
• Positive Sentiment: CFRA upgraded the stock from Hold to Buy. TD Cowen also raised its price target to $185 and maintained a Buy rating, signaling further potential upside. TD Cowen price-target change
• Neutral Sentiment: Other analysts raised targets but kept more cautious ratings: Barclays set $175 with Equal Weight, RBC set $172 with Sector Perform, and JPMorgan set $160 with Neutral. The range of views suggests analysts see improvement, but not uniform conviction. JPMorgan price-target change
• Negative Sentiment: Valuation may temper enthusiasm: coverage questioned whether the stock is now too expensive, while JPMorgan’s new target is close to the referenced share price. This could contribute to a pullback even after the earnings beat. Valuation and dividend coverage

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.